"Oxazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.
| Descriptor ID |
D010080
|
| MeSH Number(s) |
D03.383.129.462
|
| Concept/Terms |
Munchnones- Munchnones
- 1,3-Oxazolium-5-Oxides
- 1,3 Oxazolium 5 Oxides
|
Below are MeSH descriptors whose meaning is more general than "Oxazoles".
Below are MeSH descriptors whose meaning is more specific than "Oxazoles".
This graph shows the total number of publications written about "Oxazoles" by people in this website by year, and whether "Oxazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 3 | 6 |
| 2018 | 10 | 6 | 16 |
| 2019 | 2 | 2 | 4 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oxazoles" by people in Profiles.
-
Potential risk for developing severe COVID-19 disease among anabolic steroid users. BMJ Case Rep. 2021 Feb 26; 14(2).
-
Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity. J Mol Model. 2020 Nov 16; 26(12):341.
-
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs. Clin Infect Dis. 2019 11 13; 69(11):2038-2039.
-
New triazinoindole bearing thiazole/oxazole analogues: Synthesis, a-amylase inhibitory potential and molecular docking study. Bioorg Chem. 2019 11; 92:103284.
-
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019 Jan 16; 20(1):57.
-
Delamanid: does it have a role in tuberculosis treatment? Lancet Respir Med. 2019 03; 7(3):193-195.
-
Preacinetobactin not acinetobactin is essential for iron uptake by the BauA transporter of the pathogen Acinetobacter baumannii. Elife. 2018 12 18; 7.
-
Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness. Eur J Pharmacol. 2019 Jan 05; 842:373-383.
-
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. Int J Infect Dis. 2019 Jan; 78:44-49.
-
Postacute Delivery of GABAA a5 Antagonist Promotes Postischemic Neurological Recovery and Peri-infarct Brain Remodeling. Stroke. 2018 10; 49(10):2495-2503.